1. <menuitem id="nbjb9"><p id="nbjb9"></p></menuitem>
      <nav id="nbjb9"><strike id="nbjb9"><bdo id="nbjb9"></bdo></strike></nav>
      1. <s id="nbjb9"><b id="nbjb9"><noscript id="nbjb9"></noscript></b></s>
        

      2. <rt id="nbjb9"><cite id="nbjb9"><samp id="nbjb9"></samp></cite></rt>

        <rt id="nbjb9"><option id="nbjb9"></option></rt>

        CN  /  EN

        imgboxbg

        NEWS

        最新消息

        台湾华讯入驻台湾国际半导体大会

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-28 17:09
        • 访问量:

        【概要描述】此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。

        台湾华讯入驻台湾国际半导体大会

        【概要描述】此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-28 17:09
        • 访问量:
        详情

        2021年12月28日至30日,台湾华讯参展台湾国际半导体大会。

        此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021),由国际半导体产业协会(SEMI)主办。

        此次SEMICON Taiwan展会除了将汇聚逾550家厂商参展,涵盖逾2000个展位,也将聚焦第三代化合物半导体、先进制程及绿色制造、异质芯片整合等三大主题。

        SEMICON Taiwan作为全球第二大及全台最具影响力的年度半导体专业展会,是全球半导体业者掌握最新技术发展、拓展商机的重要交流平台。

        在展会期间,台湾华讯与同仁也学习了行业最新科研趋势,和各企业的精英相互学习、交流经验。

        华讯一直专注于集成电路半导体与生物医药的专利顾问服务,紧跟集成电路半导体产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国半导体产业的发展出一份力。

        关键词:

        Ruige

        Ruige Pharmaceutical's New Generation of CDK2/4/6 Small-molecule Inhibitor Receives FDA Approval for Clinical Research

        Established in 2018, Ruige Pharmaceutical?is committed to the fields of tumors, autoimmunity and metabolism, and develops "first-in-class" and "best-in-class" innovative drugs with independent intellectual property rights. Recently, Ruige Pharmaceutical?announced that its new generation of CDK2/4/6 small- molecule inhibitor RGT-419B has been received FDA approval for clinical research. RGT-419B is a new-generation tumor-targeted inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors. These inhibitors are used in combination with endocrine therapy to treat patients with premenopausal/postmenopausal hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model experiments, RGT-419B showed single-drug activity, which has a greater inhibitory effect on the growth of estrogen receptor positive (ER+) tumor cells. In ER+ breast cancer cells resistant to currently approved CDK4/6 inhibitors, RGT-419B showed complete inhibition of cancer cell proliferation. In these experiments, when RGT-419B is used in combination with a selective estrogen receptor degrader or PI3K signaling pathway inhibitor, its inhibitory effect on tumor cells is further enhanced. As a single agent and used in combination with other approved therapies, RGT-419B will initially be developed for the treatment of human epidermal growth factor receptor 2 negative (HER2-), ER+ breast cancer patients who have primary or acquired resistance to CDK4/6 inhibitors. With the widespread adoption of CDK4/6 inhibitors in clinical practice, patients with refractory and relapsed patients are becoming larger and clinically significant unmet medical needs. The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer. RGT-419B is the first of many innovative oncology drugs being developed by Ruige Pharmaceutical. Founder and CEO Dr. Qiu Xiayang said: "This milestone marks the successful entry of Ruige Pharmaceutical into the field of tumor treatment. We have found the best choice for multiple CDKs through our self-developed AI-assisted new drug development CARD platform. Successfully promoted innovative drugs to enter the clinical development stage in the United States. At the same time, we are very excited that this opportunity can bring new and differentiated treatment options to many breast cancer patients around the world.
        2021-12-30
        台湾华讯入驻台湾国际半导体大会

        台湾华讯入驻台湾国际半导体大会

        此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。
        2021-12-28
        华讯参展2021云上南京软博会

        华讯参展2021云上南京软博会

        华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。
        2021-12-27
        原告被告都是国外企业

        原告被告都是国外企业 他们竟纷纷选择到中国提起诉讼?

        这是一个有趣的趋势:由于种种原因,国外企业纷纷选择在中国提起专利诉讼,起诉非中国企业。
        2021-12-24
        上一页
        1
        2
        ...
        145
        这是描述信息

        江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

        版权所有◎南京华讯知识产权顾问有限公司

        备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京

        亚洲AV无码一区二区乱子伦,久久精品中文字幕一区,色费女人18毛片A级毛片视频,欧美+日本+国产+A∨观看